Filing Details

Accession Number:
0001209191-20-044748
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-04 17:14:06
Reporting Period:
2020-08-03
Accepted Time:
2020-08-04 17:14:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1706431 Vir Biotechnology Inc. VIR Biological Products, (No Disgnostic Substances) (2836) 812730369
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1786372 Jay Parrish C/O Vir Biotechnology, Inc.
499 Illinois Street, Suite 500
San Francisco CA 94158
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-03 9,259 $1.49 231,481 No 4 M Direct
Common Stock Acquisiton 2020-08-03 1,851 $1.58 233,332 No 4 M Direct
Common Stock Disposition 2020-08-03 11,110 $47.65 222,222 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-08-03 9,259 $0.00 9,259 $1.49
Common Stock Stock Option (Right to Buy) Disposition 2020-08-03 1,851 $0.00 1,851 $1.58
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
37,037 2027-10-05 No 4 M Direct
60,184 2028-07-19 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.
  2. 1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
  3. 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.